Kickback Investigations: What Triggers Doj Healthcare Probes?

Anti-Kickback Statute under 42 U.S.C. § 1320a-7b(b) criminalizes knowingly and willfully offering, paying, soliciting, or receiving remuneration to induce referrals for federal healthcare programs. "One purpose rule" (United States v. Greber, 760 F.2d 68, 3d Cir. 1985) holds AKS violated if any one purpose of payment is to induce referrals. AKS knowledge requirement under ACA § 6402(f) clarified that violators need not have actual knowledge or specific intent to violate the AKS. Per-violation penalties include up to 10 years imprisonment, $100,000 fine per violation, plus civil monetary penalties. Strong health care fraud counsel evaluates each remuneration arrangement against statutory elements and safe harbor availability.

DOJ Healthcare Fraud Section, U.S. Attorney Offices, and OIG (HHS Office of Inspector General) coordinate federal kickback investigations with FBI agent support. HIPAA grand jury subpoenas under 18 U.S.C. § 1518 provide healthcare-specific investigative tools beyond standard subpoenas. Civil Investigative Demands (CIDs) under 31 U.S.C. § 3733 allow government to gather pre-FCA documents and testimony without grand jury. Search warrants at provider premises, employee interviews, and parallel state Medicaid Fraud Control Unit (MFCU) investigations frequently coordinate. Strong anti-corruption investigations counsel manages government engagement and document production across multi-agency probes.

Medical directorship arrangements require fair market value compensation set in advance, commercially reasonable scope, and bona fide services not contingent on referrals. Equipment lease and space rental safe harbor requires written agreement, FMV at signing, term of at least one year, and no referral-tied payments. Recruitment arrangements must satisfy practitioner recruitment safe harbor with strict cap and timing requirements. Speaker programs and consulting agreements with pharma and device companies remain high-risk enforcement areas after Novartis and other settlements. Strong medicare law counsel reviews each arrangement against FMV standards and safe harbor elements before execution.

Pharmaceutical and device industry speaker programs face heightened OIG scrutiny following OIG Special Fraud Alert (November 2020) targeting common abusive practices. Honoraria payments, lavish meals, and inappropriate venue selection in speaker programs frequently trigger AKS investigations. Group Purchasing Organization (GPO) safe harbor under § 1001.952(j) requires written agreement, capped administrative fees, and full disclosure. Sub-distributor and resale chain arrangements require evaluation against discount safe harbor (§ 1001.952(h)) and broader AKS principles. Coordinated medicare billing fraud counsel evaluates each pharma/device arrangement against current enforcement priorities.

False Claims Act (31 U.S.C. § 3729) provides parallel civil exposure for AKS violations through "false claim" theory based on tainted reimbursement requests. ACA § 6402(g) clarified that AKS violations automatically constitute false claims under FCA, eliminating prior interpretive disputes. Qui tam relators under 31 U.S.C. § 3730 file under seal with government having 60 days to intervene or decline. Treble damages plus per-claim civil monetary penalties ($13,946-$27,894 per claim post-2024) create substantial recovery exposure. Strong false claims act counsel coordinates AKS investigation response with parallel FCA defense from initial relator complaint.

Internal investigations triggered by hotline reports, audit findings, or employee complaints require careful scope, privilege protection, and document collection. Upjohn warnings to employees during interviews establish company-counsel privilege without creating individual representation. OIG Self-Disclosure Protocol (April 2013, updated 2021) provides structured pathway for self-disclosure of AKS, Stark, and other federal healthcare violations. Self-disclosure typically results in reduced damages multiplier (1.5x vs trebled), avoidance of permissive exclusion, and limited CIA scope. Strong whistleblower counsel coordinates internal investigation, privilege strategy, and self-disclosure decision making.

Criminal AKS prosecution under § 1320a-7b(b) carries up to 10 years imprisonment, $100,000 fine per violation, and mandatory exclusion from federal healthcare programs. Federal Sentencing Guidelines § 2B4.1 (Commercial Bribery) and § 2B1.1 (loss-based table) apply to AKS cases with substantial enhancements. Plea agreements with deferred prosecution agreement (DPA) or non-prosecution agreement (NPA) protect corporate entities while individuals may face separate prosecution. Cooperation agreements with prosecutors require complete disclosure of conduct and ongoing compliance commitments. Strong medicaid fraud defense counsel manages plea negotiations, sentencing presentation, and exclusion mitigation simultaneously.

Civil settlements under FCA typically involve damages, civil monetary penalties, and Corporate Integrity Agreement (CIA) with 5-year monitoring requirements. CIA obligations include written policies, training, internal review systems, independent review organization (IRO) audits, and reporting to OIG. Permissive exclusion under 42 U.S.C. § 1320a-7(b) bars provider participation in federal healthcare programs, with industry-ending consequences. Voluntary exclusion can sometimes replace mandatory exclusion through negotiated CIA combined with structural changes. Coordinated qui tam litigation counsel evaluates settlement, CIA terms, and exclusion exposure together with whistleblower share negotiation.